220 related articles for article (PubMed ID: 32677589)
21. Neoadjuvant Chemotherapy in Triple Negative Breast Cancer: Correlation between Androgen Receptor Expression and Pathological Response.
Mohammed AA; Elsayed FM; Algazar M; Rashed HE; Anter AH
Asian Pac J Cancer Prev; 2020 Feb; 21(2):563-568. PubMed ID: 32102539
[TBL] [Abstract][Full Text] [Related]
22. Response and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.
Prat A; Fan C; Fernández A; Hoadley KA; Martinello R; Vidal M; Viladot M; Pineda E; Arance A; Muñoz M; Paré L; Cheang MC; Adamo B; Perou CM
BMC Med; 2015 Dec; 13():303. PubMed ID: 26684470
[TBL] [Abstract][Full Text] [Related]
23. Identification of Biomarkers Including 18FDG-PET/CT for Early Prediction of Response to Neoadjuvant Chemotherapy in Triple-Negative Breast Cancer.
Humbert O; Riedinger JM; Charon-Barra C; Berriolo-Riedinger A; Desmoulins I; Lorgis V; Kanoun S; Coutant C; Fumoleau P; Cochet A; Brunotte F
Clin Cancer Res; 2015 Dec; 21(24):5460-8. PubMed ID: 26130460
[TBL] [Abstract][Full Text] [Related]
24. [The influence of various myelosuppression degrees during neoadjuvant chemotherapy on the curative effect and prognosis of triple-negative breast cancer].
Niu YD; Zhang YW; Zhu RJ; Chu T; Wang L; Wang S; Li YY; Dong Y
Zhonghua Yi Xue Za Zhi; 2022 Aug; 102(29):2290-2294. PubMed ID: 35927061
[No Abstract] [Full Text] [Related]
25. Prediction of pathological complete response and prognosis in patients with neoadjuvant treatment for triple-negative breast cancer.
Gass P; Lux MP; Rauh C; Hein A; Bani MR; Fiessler C; Hartmann A; Häberle L; Pretscher J; Erber R; Wachter DL; Schulz-Wendtland R; Beckmann MW; Fasching PA; Wunderle M
BMC Cancer; 2018 Oct; 18(1):1051. PubMed ID: 30373556
[TBL] [Abstract][Full Text] [Related]
26. Tumor-Infiltrating Lymphocytes/Plasmocytes in Chemotherapeutically Non-Influenced Triple-Negative Breast Cancers - Correlation with Morphological and Clinico-Pathological Parameters.
Kolečková M; Kolář Z; Ehrmann J; Kořínková G; Zlámalová N; Melichar B; Trojanec R
Klin Onkol; 2019; 32(5):380-387. PubMed ID: 31610672
[TBL] [Abstract][Full Text] [Related]
27. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
[TBL] [Abstract][Full Text] [Related]
28. High expression of NR1D1 is associated with good prognosis in triple-negative breast cancer patients treated with chemotherapy.
Na H; Han J; Ka NL; Lee MH; Choi YL; Shin YK; Lee MO
Breast Cancer Res; 2019 Nov; 21(1):127. PubMed ID: 31779659
[TBL] [Abstract][Full Text] [Related]
29. Pembrolizumab for Early Triple-Negative Breast Cancer.
Schmid P; Cortes J; Pusztai L; McArthur H; Kümmel S; Bergh J; Denkert C; Park YH; Hui R; Harbeck N; Takahashi M; Foukakis T; Fasching PA; Cardoso F; Untch M; Jia L; Karantza V; Zhao J; Aktan G; Dent R; O'Shaughnessy J;
N Engl J Med; 2020 Feb; 382(9):810-821. PubMed ID: 32101663
[TBL] [Abstract][Full Text] [Related]
30. Prognostic impact of clinicopathologic parameters in stage II/III breast cancer treated with neoadjuvant docetaxel and doxorubicin chemotherapy: paradoxical features of the triple negative breast cancer.
Keam B; Im SA; Kim HJ; Oh DY; Kim JH; Lee SH; Chie EK; Han W; Kim DW; Moon WK; Kim TY; Park IA; Noh DY; Heo DS; Ha SW; Bang YJ
BMC Cancer; 2007 Nov; 7():203. PubMed ID: 17976237
[TBL] [Abstract][Full Text] [Related]
31. Clinical and Demographic Factors, Treatment Patterns, and Overall Survival Associated With Rare Triple-Negative Breast Carcinomas in the US.
Elimimian EB; Samuel TA; Liang H; Elson L; Bilani N; Nahleh ZA
JAMA Netw Open; 2021 Apr; 4(4):e214123. PubMed ID: 33844001
[TBL] [Abstract][Full Text] [Related]
32. Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy.
Lindner JL; Loibl S; Denkert C; Ataseven B; Fasching PA; Pfitzner BM; Gerber B; Gade S; Darb-Esfahani S; Sinn BV; Huober J; Engels K; Tesch H; Karn T; Pommerenke F; Liedtke C; Untch M; Müller V; Rack B; Schem C; von Minckwitz G
Ann Oncol; 2015 Jan; 26(1):95-100. PubMed ID: 25355716
[TBL] [Abstract][Full Text] [Related]
33. Prognostic significance of Bcl-2 expression in non-basal triple-negative breast cancer patients treated with anthracycline-based chemotherapy.
Choi JE; Kang SH; Lee SJ; Bae YK
Tumour Biol; 2014 Dec; 35(12):12255-63. PubMed ID: 25179840
[TBL] [Abstract][Full Text] [Related]
34. Predictive and prognostic value of Matrix metalloproteinase (MMP) - 9 in neoadjuvant chemotherapy for triple-negative breast cancer patients.
Wang RX; Chen S; Huang L; Shao ZM
BMC Cancer; 2018 Sep; 18(1):909. PubMed ID: 30241470
[TBL] [Abstract][Full Text] [Related]
35. Prognostic function of Ki-67 for pathological complete response rate of neoadjuvant chemotherapy in triple-negative breast cancer.
Zhang G; Xie W; Liu Z; Lin C; Piao Y; Xu L; Guo F; Xie X
Tumori; 2014; 100(2):136-42. PubMed ID: 24852856
[TBL] [Abstract][Full Text] [Related]
36. Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact.
Nabholtz JM; Abrial C; Mouret-Reynier MA; Dauplat MM; Weber B; Gligorov J; Forest AM; Tredan O; Vanlemmens L; Petit T; Guiu S; Van Praagh I; Jouannaud C; Dubray-Longeras P; Tubiana-Mathieu N; Benmammar KE; Kullab S; Bahadoor MR; Radosevic-Robin N; Kwiatkowski F; Desrichard A; Cayre A; Uhrhammer N; Chalabi N; Chollet P; Penault-Llorca F
Ann Oncol; 2014 Aug; 25(8):1570-7. PubMed ID: 24827135
[TBL] [Abstract][Full Text] [Related]
37. Coexpression of androgen receptor and FOXA1 in nonmetastatic triple-negative breast cancer: ancillary study from PACS08 trial.
Guiu S; Charon-Barra C; Vernerey D; Fumoleau P; Campone M; Spielmann M; Roché H; Mesleard C; Arnould L; Lemonnier J; Lacroix-Triki M
Future Oncol; 2015; 11(16):2283-97. PubMed ID: 26260807
[TBL] [Abstract][Full Text] [Related]
38. Influence of secreted frizzled receptor protein 1 (SFRP1) on neoadjuvant chemotherapy in triple negative breast cancer does not rely on WNT signaling.
Bernemann C; Hülsewig C; Ruckert C; Schäfer S; Blümel L; Hempel G; Götte M; Greve B; Barth PJ; Kiesel L; Liedtke C
Mol Cancer; 2014 Jul; 13():174. PubMed ID: 25033833
[TBL] [Abstract][Full Text] [Related]
39. Evaluation with 3.0-T MR imaging: predicting the pathological response of triple-negative breast cancer treated with anthracycline and taxane neoadjuvant chemotherapy.
Kim MJ; Kim EK; Park S; Moon HJ; Kim SI; Park BW
Acta Radiol; 2015 Sep; 56(9):1069-77. PubMed ID: 25228161
[TBL] [Abstract][Full Text] [Related]
40. Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy.
Darb-Esfahani S; Denkert C; Stenzinger A; Salat C; Sinn B; Schem C; Endris V; Klare P; Schmitt W; Blohmer JU; Weichert W; Möbs M; Tesch H; Kümmel S; Sinn P; Jackisch C; Dietel M; Reimer T; Loi S; Untch M; von Minckwitz G; Nekljudova V; Loibl S
Oncotarget; 2016 Oct; 7(42):67686-67698. PubMed ID: 27611952
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
